Analysts at Robert W. Baird lowered their price target on Intermune's (Nasdaq: ITMN) to $13 from $41 after the FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE